D
Vincerx Pharma, Inc.
VINC
$0.809
-$0.0102-1.25%
D
Sell
2/24/2025Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 2/24/2025 due to a major increase in the solvency index and volatility index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 2/24/2025 due to a major increase in the solvency index and volatility index.
E
Sell
7/25/2024Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 7/25/2024 due to a decline in the total return index and volatility index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 7/25/2024 due to a decline in the total return index and volatility index.
D
Sell
7/10/2024Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 7/10/2024 due to an increase in the volatility index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 7/10/2024 due to an increase in the volatility index.
E
Sell
6/24/2024Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 6/24/2024 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.2316 to -$0.5808, the quick ratio declined from 2.51 to 0.58, and EBIT declined 35.15% from -$5.53M to -$7.48M.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 6/24/2024 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.2316 to -$0.5808, the quick ratio declined from 2.51 to 0.58, and EBIT declined 35.15% from -$5.53M to -$7.48M.
D
Sell
4/18/2024Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 4/18/2024 due to an increase in the valuation index and total return index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 4/18/2024 due to an increase in the valuation index and total return index.
E
Sell
3/1/2024Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 3/1/2024 due to a decline in the valuation index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 3/1/2024 due to a decline in the valuation index.
D
Sell
2/9/2024Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 2/9/2024 due to an increase in the total return index and volatility index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 2/9/2024 due to an increase in the total return index and volatility index.
E
Sell
8/29/2023Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index and total return index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index and total return index.
D
Sell
8/9/2023Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 8/9/2023 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 22.78% from -$15.1M to -$11.66M, earnings per share increased from -$0.6768 to -$0.5242, and operating cash flow increased 3.02% from -$13.09M to -$12.7M.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 8/9/2023 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 22.78% from -$15.1M to -$11.66M, earnings per share increased from -$0.6768 to -$0.5242, and operating cash flow increased 3.02% from -$13.09M to -$12.7M.
E
Sell
7/25/2023Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 7/25/2023 due to a decline in the volatility index and total return index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 7/25/2023 due to a decline in the volatility index and total return index.
D
Sell
7/6/2023Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index, total return index and valuation index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
6/16/2023Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 6/16/2023 due to a decline in the volatility index and valuation index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 6/16/2023 due to a decline in the volatility index and valuation index.
D
Sell
5/22/2023Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 5/22/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 5.25% from -$13.82M to -$13.09M, and EBIT increased 2.1% from -$15.42M to -$15.1M.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 5/22/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 5.25% from -$13.82M to -$13.09M, and EBIT increased 2.1% from -$15.42M to -$15.1M.
E
Sell
5/18/2023Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 5/18/2023 due to a decline in the volatility index and growth index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 5/18/2023 due to a decline in the volatility index and growth index.
D
Sell
4/28/2023Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 4/28/2023 due to an increase in the volatility index and total return index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 4/28/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D on 03/14/2023.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D from E+ on 02/09/2023.
Vincerx Pharma, Inc. (VINC) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the valuation index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the valuation index.
D
Sell
1/24/2023Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to D- from D on 1/24/2023 due to a decline in the volatility index.
Vincerx Pharma, Inc. (VINC) was downgraded to D- from D on 1/24/2023 due to a decline in the volatility index.
D
Sell
1/4/2023Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 1/4/2023 due to an increase in the volatility index.
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 1/4/2023 due to an increase in the volatility index.
D
Sell
12/15/2022Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index and total return index.
Vincerx Pharma, Inc. (VINC) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index and total return index.
D
Sell
11/14/2022Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 11/14/2022 due to a major increase in the growth index. EBIT increased 15.56% from -$18.46M to -$15.59M, earnings per share increased from -$0.8774 to -$0.8006, and operating cash flow increased 6.39% from -$15.89M to -$14.87M.
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 11/14/2022 due to a major increase in the growth index. EBIT increased 15.56% from -$18.46M to -$15.59M, earnings per share increased from -$0.8774 to -$0.8006, and operating cash flow increased 6.39% from -$15.89M to -$14.87M.
D
Sell
11/3/2022Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 11/3/2022 due to an increase in the volatility index and total return index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 11/3/2022 due to an increase in the volatility index and total return index.
E
Sell
10/19/2022Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 10/19/2022 due to a decline in the volatility index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 10/19/2022 due to a decline in the volatility index.
D
Sell
9/22/2022Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 9/22/2022 due to an increase in the volatility index and total return index.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 9/22/2022 due to an increase in the volatility index and total return index.
E
Sell
9/7/2022Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 9/7/2022 due to a decline in the volatility index.
Vincerx Pharma, Inc. (VINC) was downgraded to E+ from D- on 9/7/2022 due to a decline in the volatility index.
D
Sell
8/19/2022Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 8/19/2022 due to an increase in the growth index, volatility index and valuation index. EBIT increased 14.63% from -$21.63M to -$18.46M.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E+ on 8/19/2022 due to an increase in the growth index, volatility index and valuation index. EBIT increased 14.63% from -$21.63M to -$18.46M.
E
Sell
5/13/2022Downgrade
Vincerx, Inc. (VINC) was downgraded to E+ from D on 5/13/2022 due to a substantial decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.3105 to -$0.786, operating cash flow declined 30.84% from -$11.49M to -$15.03M, and EBIT declined 22.14% from -$17.71M to -$21.63M.
Vincerx, Inc. (VINC) was downgraded to E+ from D on 5/13/2022 due to a substantial decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.3105 to -$0.786, operating cash flow declined 30.84% from -$11.49M to -$15.03M, and EBIT declined 22.14% from -$17.71M to -$21.63M.
D
Sell
5/4/2022Upgraded
Vincerx, Inc. (VINC) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Vincerx, Inc. (VINC) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Vincerx, Inc. (VINC) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Vincerx, Inc. (VINC) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D from E+ on 04/21/2022.
Vincerx Pharma, Inc. (VINC) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Vincerx, Inc. (VINC) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
Vincerx, Inc. (VINC) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
3/30/2022Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 3/30/2022 due to a major increase in the growth index. Earnings per share increased from -$1.386 to -$0.3118, and EBIT increased 1.25% from -$17.93M to -$17.71M.
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 3/30/2022 due to a major increase in the growth index. Earnings per share increased from -$1.386 to -$0.3118, and EBIT increased 1.25% from -$17.93M to -$17.71M.
D
Sell
2/18/2022Downgrade
Vincerx Pharma, Inc. (VINC) was downgraded to D- from D on 2/18/2022 due to a substantial decline in the total return index, efficiency index and volatility index. Net income declined 1,105.7% from -$2.03M to -$24.52M.
Vincerx Pharma, Inc. (VINC) was downgraded to D- from D on 2/18/2022 due to a substantial decline in the total return index, efficiency index and volatility index. Net income declined 1,105.7% from -$2.03M to -$24.52M.
D
Sell
11/3/2021Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 11/3/2021 due to a significant increase in the total return index, volatility index and valuation index.
Vincerx Pharma, Inc. (VINC) was upgraded to D from D- on 11/3/2021 due to a significant increase in the total return index, volatility index and valuation index.
D
Sell
9/1/2021Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E on 9/1/2021 due to a noticeable increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.83 to 5.46, and earnings per share increased from -$0.4569 to -$0.1244.
Vincerx Pharma, Inc. (VINC) was upgraded to D- from E on 9/1/2021 due to a noticeable increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.83 to 5.46, and earnings per share increased from -$0.4569 to -$0.1244.
E
Sell
6/1/2021Upgraded
Vincerx Pharma, Inc. (VINC) was upgraded to E from E- on 6/1/2021 due to an increase in the valuation index and total return index.
Vincerx Pharma, Inc. (VINC) was upgraded to E from E- on 6/1/2021 due to an increase in the valuation index and total return index.
E
Sell
3/24/2021None
Vincerx Pharma, Inc. (VINC) was downgraded to E- from U on 03/24/2021.
Vincerx Pharma, Inc. (VINC) was downgraded to E- from U on 03/24/2021.
NASDAQ
03/12/2025 4:00PM Eastern
Quotes delayed
